{"slug":"kpv","seoKey":"kpv","displayName":"KPV","codes":["H-Lys-Pro-Val-OH"],"synonyms":["Lys-Pro-Val","lysine-proline-valine","alpha-MSH (11-13)","MSH (11-13)","ACTH (11-13)","L-lysyl-L-prolyl-L-valine","KPV acetate"],"legalClass":"research_chemical","identifiers":{"cas":"67727-97-3","pubchemCid":125672,"inchikey":"YSPZCHGIWAQVKQ-AVGNSLFASA-N","wikidataQid":"Q82975228","formula":"C16H30N4O4","molecularWeight":342.43,"sequence":"KPV"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved in any indication and no pharmacopoeial monograph. Listed among the bulk drug substances nominated for compounding but withdrawn by the nominators; not on the 503A bulks list on 2026-09-06.","source":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"market":"EU","status":"not_approved","note":"No authorised medicinal product and no monograph in the European Pharmacopoeia. No entry found on 2026-09-06.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=KPV"},{"market":"DE","status":"not_approved","note":"No national or EU marketing authorisation; a substance with a medicinal purpose may not be placed on the market without one. No entry found on 2026-09-06.","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=KPV"},{"market":"UK","status":"not_approved","note":"No marketing authorisation; treated as an unlicensed medicine. No entry found on 2026-09-06.","source":"https://products.mhra.gov.uk/search/?search=KPV"},{"market":"AU","status":"not_approved","note":"Not named in the Poisons Standard; a full-text search on 2026-09-06 returned no entry. Absence of a listing does not make the substance freely available, since unapproved therapeutic goods remain regulated.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"No marketing authorisation and no drug identification number. No entry found on 2026-09-06.","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=KPV"},{"market":"CH","status":"not_approved","note":"No marketing authorisation. No entry found in the Swiss medicinal product information on 2026-09-06.","source":"https://www.swissmedicinfo.ch/"}],"devStage":"preclinical","strongestEvidence":"animal","wada":{"status":"prohibited","section":"S0","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://www.wikidata.org/wiki/Q82975228","https://pubchem.ncbi.nlm.nih.gov/compound/125672"],"lastVerified":"2026-09-06","version":"1.0","published":true,"locale":"en","title":"KPV: what the studies show, status and safety","summary":"KPV is a fragment of just three building blocks taken from the hormone alpha-MSH, and it is sold as a research peptide. Not a single study in people exists, and no safety testing has been done in any species at all. Animal work on inflamed bowels and on injured corneas does report effects, but nobody knows where in the cell the peptide acts, and the receptors that its parent hormone uses have been ruled out. No country has approved it.","updated":"2026-09-06","url":"https://mypep.app/peptides/kpv"}